TriangleNCT04146038 · OUTCOME
Number of Participants Experiencing Adverse Events Incidence With of Salicylate + Venetoclax + Decitabine
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- COUNT_OF_PARTICIPANTS
- Unit
- Participants
- Interval / dispersion
- Not reported
- Time frame
- During the first 2 cycles, 56 days total
What was measured
Study drug associated adverse events during therapy
Groups in this outcome
Treatment (Salsalate, Decitabine, Azacitidine, Venetoclax)
CYCLE 1: Patients receive salsalate PO BID until completion of cycle 1. 24-48 hours later or concurrent with salsalate, patients begin to receive decitabine IV for 10 days or azacitidine IV for 7 days. Starting 24 hour after salsalate, patients also receive venetoclax PO continuously until completion of cycle 1. CYCLE 2: Patients receive decitabine IV for 5 days or azacitidine IV for 7 days, salsalate PO BID, and venetoclax PO continuously. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Azacitidine: Given IV Decitabine: Given IV Salsalate: Given PO Venetoclax: Given PO
| Group | Source count |
|---|---|
| Treatment (Salsalate, Decitabine, Azacitidine, Venetoclax) | 5 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Treatment (Salsalate, Decitabine, Azacitidine, Venetoclax) | 1 | Not reported | Not reported | Not reported | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- value
- 1
- denoms
- counts
- group Id
- OG000
- value
- 5
- units
- Participants
- description
- Study drug associated adverse events during therapy
- groups
- description
- CYCLE 1: Patients receive salsalate PO BID until completion of cycle 1. 24-48 hours later or concurrent with salsalate, patients begin to receive decitabine IV for 10 days or azacitidine IV for 7 days. Starting 24 hour after salsalate, patients also receive venetoclax PO continuously until completion of cycle 1. CYCLE 2: Patients receive decitabine IV for 5 days or azacitidine IV for 7 days, salsalate PO BID, and venetoclax PO continuously. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Azacitidine: Given IV Decitabine: Given IV Salsalate: Given PO Venetoclax: Given PO
- id
- OG000
- title
- Treatment (Salsalate, Decitabine, Azacitidine, Venetoclax)
- param Type
- COUNT_OF_PARTICIPANTS
- reporting Status
- POSTED
- time Frame
- During the first 2 cycles, 56 days total
- title
- Number of Participants Experiencing Adverse Events Incidence With of Salicylate + Venetoclax + Decitabine
- type
- PRIMARY
- unit Of Measure
- Participants
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice